ACUMEN PHARMACEUTICALS SHARES EXTEND LOSSES AFTER CO'S ALZHEIMER'S DRUG MISSES PRIMARY ENDPOINT IN MID-STAGE TRIAL; LAST DOWN 85.9%

Reuters · 4d ago

Please log in to view news